NASD · Healthcare · Biotechnology · USA
Adma Biologics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
ADMA Biologics manufactures and markets specialty biologics derived from blood plasma for treating immunodeficient patients at risk for infections. The company produces three FDA-approved products: ASCENIV and BIVIGAM for primary immunodeficiency, and Nabi-HB for hepatitis B exposure. It operates a plasma fractionation facility in Florida and owns plasma collection centers that supply raw materials and serve third-party customers.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Adma Biologics Inc stock.
Undervalued: intrinsic value $17.29 per share, market price $13.63, margin of safety 21.2% (as of 2026-11-17).
Discounting its cash flows at 8.6% (average of 3 methods) values the shares at $17.29; the price of $13.63 is 21% below that value, and 79% of that value comes from beyond year five.
17 more funds hold it; the full list is part of the paid plan.
14 more in this industry show a wider margin of safety.
ADMA is undervalued (as of the 2026-11-17 close). Discounting its cash flows at 8.6% (average of 3 methods) values the shares at $17.29; the price of $13.63 is 21% below that value, and 79% of that value comes from beyond year five.
$17.29 per share (as of the 2026-11-17 close), against a market price of $13.63. That is a margin of safety of 21.2%. The value is the average of the 3 valuation methods that apply to this company, recomputed every night after the US close.